Lajos Pusztai
Medical Oncology · New Haven, CTNPI 1437241510
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $110,649 of the $151,923 with a category attached, or 72.8%. 20 manufacturers reported payments, led by Merck at 32.7% of the total.
Across 136 payments — averaging $1117.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$50K
- AstraZeneca$25K
- Astrazeneca UK Limited$16K
- Novartis$16K
- E.r. Squibb & Sons, L.L.C.$8K
- Gilead$6K
- plus $32K from 14 others
Across 255 payments — averaging $91,522 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$20.9M
- AstraZeneca$1.5M
- Merck$543K
- Seagen Inc.$401K
- GSK$39K
- Genentech, Inc.$26K
- plus $4K from 2 others
What the payments were for
- Consulting fees$110,64973%
- Speaking & faculty fees$33,30522%
- Grants$2500%
- Travel & lodging$3,6782%
- Food & beverage$4,0303%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 22 | $49,698 |
| AstraZeneca | 40 | $24,969 |
| Astrazeneca UK Limited | 17 | $16,219 |
| Novartis | 7 | $15,552 |
| E.r. Squibb & Sons, L.L.C. | 7 | $7,565 |
| Gilead | 8 | $5,838 |
| Pfizer | 8 | $4,846 |
| Jazz Pharmaceuticals Inc. | 1 | $4,120 |
| F. Hoffmann-la Roche AG | 2 | $4,110 |
| GSK | 2 | $4,000 |
| Radius Health, Inc. | 4 | $3,089 |
| Stemline Therapeutics Inc. | 2 | $2,560 |
| Daiichi Sankyo Inc. | 1 | $2,055 |
| Beone Medicines USA, Inc. | 3 | $1,849 |
| Clovis Oncology, Inc. | 2 | $1,613 |
| Tersera Therapeutics LLC | 3 | $1,440 |
| Foundation Medicine, Inc. | 2 | $927 |
| Genentech USA, Inc. | 3 | $868 |
| Athenex Pharmaceutical Division, LLC | 1 | $500 |
| Seagen Inc. | 1 | $105 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$151,923 in reported general payments places this provider in the 85th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 12 | $188,332 |
| Anastrozole | 125 | $2,696 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Haven
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Francine FossNew Haven$193K
- Anne ChiangNew Haven$158K
- Mario SznolNew Haven$157K
- Howard HochsterNew Haven$133K
- Sarah GoldbergNew Haven$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.